Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Johnson & Johnson

Pennsylvania Department of Community and Economic Development
Pennsylvania / Small Business

Pennsylvania’s Business Boom Defies the Odds as Survival Rates Soar

January 12, 2026January 12, 2026 - by Maryann Pugh

HARRISBURG, PA — Pennsylvania is quietly pulling off what many states only promise: keeping new businesses alive long enough to thrive. New federal data shows that 56 percent of companies …

Pennsylvania’s Business Boom Defies the Odds as Survival Rates Soar Read More

Johnson & Johnson
Regional

J&J’s Lupus Breakthrough Sets the Stage for a High-Stakes Phase 3 Push

January 11, 2026January 10, 2026 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) said its experimental immune therapy nipocalimab cleared a major clinical hurdle in systemic lupus erythematosus, delivering the first positive Phase 2b …

J&J’s Lupus Breakthrough Sets the Stage for a High-Stakes Phase 3 Push Read More
Johnson & Johnson
Regional

FDA Clears Five-Minute Lung Cancer Shot, Redefining EGFR Treatment

December 27, 2025December 24, 2025 - by Timothy Alexander

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has won U.S. Food and Drug Administration approval for RYBREVANT FASPRO, the first and only subcutaneous therapy for patients with EGFR-mutated non-small …

FDA Clears Five-Minute Lung Cancer Shot, Redefining EGFR Treatment Read More

Johnson & Johnson
Regional

FDA Clears Breakthrough Precision Combo for Aggressive Prostate Cancer

December 18, 2025December 18, 2025 - by Timothy Alexander

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has approved an expanded indication for AKEEGA, clearing the first FDA-approved precision medicine combination for …

FDA Clears Breakthrough Precision Combo for Aggressive Prostate Cancer Read More
Johnson & Johnson
Regional

FDA Approves First Treatment for High-Risk Smoldering Multiple Myeloma

November 15, 2025November 12, 2025 - by Timothy Alexander

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as the first-ever treatment for adults with …

FDA Approves First Treatment for High-Risk Smoldering Multiple Myeloma Read More

Johnson & Johnson
Regional

Johnson & Johnson Launches First Head-to-Head Study of IMAAVY in Myasthenia Gravis

November 8, 2025November 5, 2025 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced plans to launch the first-ever head-to-head study comparing its FcRn blocker IMAAVY™ (nipocalimab-aahu) with efgartigimod in adults living with generalized …

Johnson & Johnson Launches First Head-to-Head Study of IMAAVY in Myasthenia Gravis Read More
Johnson & Johnson
Regional

New Study Finds Psoriasis Patients Favor Oral Treatments Over Injections

November 8, 2025November 5, 2025 - by Timothy Alexander

SPRING HOUSE, PA — A new U.S. study from Johnson & Johnson (NYSE: JNJ) reveals that most people living with psoriasis — and their healthcare providers — strongly prefer effective …

New Study Finds Psoriasis Patients Favor Oral Treatments Over Injections Read More

Johnson & Johnson
Regional

Johnson & Johnson’s Oral Psoriasis Drug Shows Strong Long-Term Results

November 4, 2025November 2, 2025 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced new one-year data showing that its investigational oral drug icotrokinra continues to demonstrate high rates of durable skin clearance and …

Johnson & Johnson’s Oral Psoriasis Drug Shows Strong Long-Term Results Read More
Johnson & Johnson
Regional

Johnson & Johnson’s TREMFYA® Shows Sustained One-Year Efficacy in Ulcerative Colitis

October 14, 2025October 13, 2025 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) released new 48-week results from its Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) as a subcutaneous induction and maintenance therapy for …

Johnson & Johnson’s TREMFYA® Shows Sustained One-Year Efficacy in Ulcerative Colitis Read More
Johnson & Johnson
Regional

Johnson & Johnson Reports Positive Phase 2b Results for Oral Ulcerative Colitis Therapy

October 13, 2025October 13, 2025 - by Timothy Alexander

SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced new data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra, an investigational oral therapy for adults with moderately to …

Johnson & Johnson Reports Positive Phase 2b Results for Oral Ulcerative Colitis Therapy Read More

Posts pagination

1 2 … 4 Next

Trending News

  • A New Cookie Joins a Historic Season as Girl Scouts Kick Off 2026 Sales

  • Pa. Lawmakers Move to Purge ‘Forever Chemicals’ From Daily Products

  • $3.6M Surge for Parks and Trails Transforms SD44 Communities

  • Gunfire Outside Small-Town Bar Lands Repeat Felon Convicted, Faces Sentencing

  • $8 Late Fee Cap Returns as Senators Target Banks’ Credit Card Profits

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

A person running on green grass field

$3.6M Surge for Parks and Trails Transforms SD44 Communities

January 16, 2026January 16, 2026

Court News

Gunfire Outside Small-Town Bar Lands Repeat Felon Convicted, Faces Sentencing

January 16, 2026January 16, 2026

Arrest

Six Felonies Filed in Alleged Ghost Gun Pipeline Feeding Philly Streets

January 16, 2026January 16, 2026

Copyright © 2026 MyChesCo.